Inhibitors of influenza viral entry
AssigneesThe Board of Trustees of the University of Illinois, Chicago Biosolutions, Inc.
InventorsLijun Rong, Irina Gaisina, Gregory R. Thatcher, Norton Peet
Life of this patent
Estimating the term…
Abstract
Vaccination is the most prevalent prophylactic means for controlling seasonal influenza infections. However, an effective vaccine usually takes at least 6 months to develop for the circulating strains. Therefore, new therapeutic options are needed for acute treatment of influenza infections to control this virus and prevent epidemic/pandemic situations from developing. Described herein are fast-acting, orally active acylated amino-substituted heterocyclyl compounds effective to control this virus. In one aspect, described herein is a method of treating an influenza infection in a subject comprising administering to the subject the compounds described herein.
Claims15
A compound is selected from the group of compounds consisting of:
- wherein
- X is CH or N;
- Rd is one to nine substituents independently selected from alkyl, halo, haloalkyl, aryl, arylalkyl and C3-C5 cycloalkyl;
- Rf is selected from H, alkyl, aryl, and arylalkyl;
- Re is one to five substituents independently selected from halo, haloalkyl, aryl, arylalkyl and —NO2;
- Rg is one to four substituents independently selected from halo, haloalkyl, aryl, arylalkyl and C3-C5 cycloalkyl, and
- Ra, Rb and Rc are independently selected from H, alkyl and aryl, or any two of Ra, Rb and Rc, together with the C atom to which they are attached define a cycloalkyl, or a pharmaceutically acceptable salt thereof.
A compound of formula II or a pharmaceutically acceptable salt thereof
- wherein
- Rh is alkyl or cycloalkyl;
- and
- Re is haloalkyl, X is CH, and n is 1 to 4, and Rf is H or Me.
A compound selected from the group of compounds consisting of:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.